European Companies Search Engine
EU funding (€8,728,185): Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy Hor26 Nov 2020 EU Research and Innovation programme "Horizon"
Text
Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy
Immune cells that are empowered by gene-engineering to seek and destroy cancer cells (engineered T cell therapy) constitute a transformative novel treatment that has the potential to cure cancer. Multiple new versions of this therapy are being developed for distinct types of cancer but their introduction into clinical practice is hampered by a lack of standardized and validated models to predict safety and efficacy, customized manufacturing and monitoring to scale up production and clinical use to industry standard, and strategies for optimal patient conditioning. The T2EVOLVE consortium unites scientists and physicians, regulators and policy makers, SMEs, and patient stakeholders to tackle these challenges in an orchestrated multi-disciplinary multi-stakeholder approach. A core feature of this approach will be the embedding of patient stakeholders as contributing members of the team across all levels of the R&D process. The overall aim is the development of an innovation ecosystem that will accelerate the process of developing engineered T cell therapy in the EU. The project will deliver novel tools for education and for improving the communication between healthcare providers and patients, optimized laboratory models that can help determine how safe and effective new therapies with engineered T cells are, standardized methods in which these therapies are produced and monitored during treatment. The consortium members are innovators and pioneers in this field that are dedicated to bringing the EU to the forefront of the global engineered T cell therapy movement. This effort will ensure that EU citizens will continue to have access to the most innovative and best-available medical care, provide guidance on how to implement this novel treatment into the EU health care system in a sustainable way, and secure a leading role for Europe in this emerging field in medicine and science, the economy and society.
Funded Companies:
| Company name | Funding amount |
| €718,625 | |
| Astellas Pharma Europe B.V. | €0.00 |
| BAYER AG | €0.00 |
| BUNDESINSTITUT für IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | €479,000 |
| Biosci Consulting BVBA | €476,000 |
| CELGENE MANAGEMENT Sàrl | €0.00 |
| Erasmus Universiteit Rotterdam | €78,125 |
| European Cancer Patient Coalition | €37,621 |
| €0.00 | |
| €0.00 | |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | €539,750 |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | €510,689 |
| Hospital Clinic de Barcelona | €0.00 |
| Information Technology FOR Translational Medicine (Ittm) SA | €312,500 |
| €454,000 | |
| Institut National du Cancer GIP | €551,260 |
| Institut de Recerca de L'Hospital de La Santa Creu i Sant Pau Fundacion | €271,310 |
| Institut de Recherches Internationales Servier Iris | €0.00 |
| Janssen Pharmaceutica N.V. | €0.00 |
| MILTENYI BIOTEC B.V. & Co. KG | €277,500 |
| Medizinische Universitaet Wien | €571,911 |
| Ospedale Pediatrico Bambino Gesu | €560,600 |
| PATVOCATES GmbH | €87,600 |
| Stichting Amsterdam UMC | €0.00 |
| T-CURX GmbH | €253,750 |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | €0.00 |
| TECHNISCHE UNIVERSITAET MUENCHEN | €562,750 |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | €612,774 |
| Universidad de Navarra | €271,370 |
| Universita Vita-Salute SAN Raffaele | €629,550 |
| €471,500 |
Source: https://cordis.europa.eu/project/id/945393
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Academisch Medisch Centrum BIJ DE Universiteit Van Amsterdam - EU funding (€8,728,185): Accelerating Development and Improving Access to CAR and TCR-engineered T cell therapy"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
